Cerevance has dosed the first participant in a Phase 2 clinical trial evaluating the safety and efficacy of its investigational oral therapy CVN424 for Parkinson’s disease. The ASCEND trial (NCT06006247) will explore the safety and efficacy of CVN424 as a single therapy in people with early-stage…
Mission Therapeutics’ experimental oral therapy MTX325, for Parkinson’s disease, spurred brain cells in mice to clear damaged mitochondria — the powerhouses of the cells — ultimately protecting them from death caused by toxic alpha-synuclein protein clumping. That’s according to the findings of a new study using a Parkinson’s…
A pilot trial into whether deep brain stimulation based on noninvasive neuromodulation of a lower leg nerve can safely and effectively ease symptoms of Parkinson’s disease and essential tremor is fully enrolled, Stimvia, its developer, announced. The 24 patients in the study (NCT06036368) will use the company’s…
An implanted device that delivers electrical stimulation to nerve cells in the spine helped reduce gait freezing in a man with Parkinson’s disease, improving his ability to walk. Gait freezing occurs when a person stops walking without meaning to, which can lead to falls. The device’s development was described…
UB-312, an experimental vaccine being developed for Parkinson’s disease by Vaxxinity, induced the production of antibodies targeting alpha-synuclein and slowed protein clumping in patients’ cerebrospinal fluid (CSF), the fluid that surrounds the brain and the spinal cord. The vaccine is designed to stimulate a patient’s immune system…
Toxic clumping of the alpha-synuclein protein, a hallmark of Parkinson’s disease, may lead to a calcium imbalance in which the mineral builds up to harmful levels in neurons early in the course of the neurodegenerative condition, according to a study in mouse and human cells. Single molecules of alpha-synuclein…
Compounds extracted from marigold flowers may be useful in treating Parkinson’s disease, according to a study done in laboratory models. The study, “Active compounds from Calendula officinalis flowers act via PI3K and ERK signaling pathways to offer neuroprotective effects against Parkinson’s disease,” was published in Food…
Biopas Laboratories has asked the regulatory agencies of six countries in Latin America to approve Inbrija for Parkinson’s disease off periods, according to Acorda Therapeutics, the therapy’s developer and Biopas’ partner. Inbrija is a self-administered, inhaled levodopa therapy developed to reduce periods when motor symptoms are…
For people with Parkinson’s disease associated with mutations in the GBA gene, deep brain stimulation (DBS) may offer lasting motor benefits and help manage impulsive-compulsive behaviors, a study suggests. Despite experiencing faster cognitive decline following DBS when compared to patients with these mutations, most patients had not developed dementia…
Major problems with sensation in the airways — essential in preventing the dysphagia or swallowing difficulties that can lead to complications like aspiration pneumonia — were not observed between Parkinson’s disease patients and healthy adults in a small recent study. But given the proposed relationship between airway sensory impairments…
Get regular updates to your inbox.
